News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
AstraZeneca PLC (JOBS) Still Awaiting FDA News on Onglyza
July 31, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, July 31 (Reuters) - AstraZeneca (AZN.L) is still waiting to hear if the U.S. Food and Drug Administration will approve its new diabetes drug Onglyza but is confident on the product's prospects, a spokesman said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
AstraZeneca Pharmaceuticals LP
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
HIV
Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries
September 5, 2025
·
1 min read
·
Tristan Manalac
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
·
4 min read
·
Annalee Armstrong
CDC
ACIP Revamp Continues as Kennedy Eyes Seven New CDC Vaccine Advisors
September 4, 2025
·
2 min read
·
Dan Samorodnitsky
Regulatory
‘All Wrapper, No Gift’: FDA Releases New Rare Disease Approval Framework
September 4, 2025
·
2 min read
·
Tristan Manalac